A Study of Anlotinib Combined With or Without PD-1 Antibody on Unresectable High-grade Chondrosarcoma

Summary

There is no standard treatment for chondrosarcoma. Some small sample of studies has shown that anti-angiogenic TKIs show certain activity in the treatment of chondrosarcoma. PD-1 inhibitors, in recent years, have also been used in clinical practice and showed good efficacy. We intend to explore the response of chondrosarcoma to PD-1 monoclonal antibody and the influence of different IDH genotypes on PD-1 monoclonal antibody response.

Timeline

Start

2023-02-06

Primary completion

2025-03-31

Completion

2026-03-31

Outcome

Met primary endpoint

paper combination treatment showed significantly improved outcomes compared to anlotinib alone in the entire population, with a higher 6-month PFSR (60.0% versus 31.4%). PMID 40882625 ↗

Publications

• Li B, Xie L, Liang J, Jiang Y, Wang K, Liu Y, Lin N, Huang X, Zhao K, Fan G, Liu M, Yan X, Qu H, Li H, Yang J, Zhou G, Ye Z. Anti-PD-1 antibody plus anlotinib vs. anlotinib alone in patients with refractory chondrosarcoma: A multicenter, non-randomized phase 2 FLAIL-C trial. Med. 2025 Nov 14;6(11):100809. doi: 10.1016/j.medj.2025.100809. Epub 2025 Aug 28.

Drugs

Indications